Breaking News, Collaborations & Alliances

Piramal, NewAmsterdam Pharma Open Dedicated OSD Form Suite

The investment provides NewAmsterdam Pharma with commercial capacity for a fixed-dose combination of obicetrapib and ezetimibe to meet potential commercial demand.

Author Image

By: Charlie Sternberg

Associate Editor

L-R: Stu Needleman, CCO and Chief Patient Centricity Officer, Piramal Pharma Solutions; Douglas Kling, COO, NewAmsterdam Pharma; Sheng Cui, CMO, NewAmsterdam Pharma; Mahesh Kulkarni, Ph.D., Senior Director, Drug Product, NewAmsterdam Pharma; Manoj Zalpuri, North American Operations Head, Piramal Pharma Solutions; Ian Smart, Managing Partner, Verta Life Sciences; and Daniel Kloss, Sellersville Site Head, Piramal Pharma Solutions.

Piramal Pharma Solutions, a global Contract Development and Manufacturing Organization (CDMO), and NewAmsterdam Pharma Company N.V. have opened a dedicated oral solid dosage (OSD) form suite at Piramal’s facility in Sellersville, Pennsylvania, USA. This addition aims to increase operational efficiency, helping NewAmsterdam Pharma to deliver its investigational drug therapy, if approved, to patients in need. The suite represents a multi-million-dollar investment in equipment upgrades ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters